This company has been acquired
La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
LogicBio Therapeutics Crescita futura
Future criteri di controllo 0/6
Informazioni chiave
n/a
Tasso di crescita degli utili
-1.2%
Tasso di crescita dell'EPS
Biotechs crescita degli utili | 28.4% |
Tasso di crescita dei ricavi | -132.5% |
Rendimento futuro del capitale proprio | n/a |
Copertura analitica | Low |
Ultimo aggiornamento | n/a |
Aggiornamenti recenti sulla crescita futura
Recent updates
LogicBio jumps 648% on buyout deal with AstraZeneca unit Alexion
Oct 03Bullish: Analysts Just Made A Notable Upgrade To Their LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Forecasts
Aug 20LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates
Aug 18LogicBio GAAP EPS of -$0.15, revenue of $3.2M
Aug 15Is LogicBio Therapeutics (NASDAQ:LOGC) Weighed On By Its Debt Load?
Jan 11Does LogicBio Therapeutics (NASDAQ:LOGC) Have A Healthy Balance Sheet?
Aug 18LogicBio EPS misses by $0.06, beats on revenue
May 10LogicBio announces agreements with CANbridge Pharma and Daiichi Sankyo
Apr 27Is LogicBio Therapeutics (NASDAQ:LOGC) Using Debt Sensibly?
Apr 12Is LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Popular Amongst Insiders?
Mar 08The LogicBio Therapeutics (NASDAQ:LOGC) Share Price Has Gained 12% And Shareholders Are Hoping For More
Jan 15LogicBio extends collaboration with Children's Medical Research Institute
Jan 07LogicBio Therapeutics names new CFO
Dec 22Looking In On LogicBio
Nov 17LogicBio reports Q3 results
Nov 09Previsioni di crescita degli utili e dei ricavi
Data | Ricavi | Guadagni | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
---|---|---|---|---|---|
12/31/2023 | N/A | N/A | -28 | N/A | 1 |
12/31/2022 | 10 | N/A | -27 | N/A | 2 |
9/30/2022 | 11 | -27 | -25 | -25 | N/A |
6/30/2022 | 10 | -31 | -29 | -28 | N/A |
3/31/2022 | 8 | -36 | -22 | -21 | N/A |
12/31/2021 | 5 | -40 | -20 | -19 | N/A |
9/30/2021 | 4 | -38 | -22 | -21 | N/A |
6/30/2021 | 3 | -36 | -17 | -17 | N/A |
3/31/2021 | 3 | -33 | -30 | -29 | N/A |
12/31/2020 | 3 | -33 | -29 | -29 | N/A |
9/30/2020 | 3 | -37 | -34 | -33 | N/A |
6/30/2020 | 2 | -40 | -39 | -38 | N/A |
3/31/2020 | 1 | -42 | -39 | -38 | N/A |
12/31/2019 | N/A | -40 | -40 | -39 | N/A |
9/30/2019 | N/A | -32 | -33 | -32 | N/A |
6/30/2019 | N/A | -29 | -27 | -26 | N/A |
3/31/2019 | N/A | -23 | -21 | -20 | N/A |
12/31/2018 | N/A | -18 | -16 | -15 | N/A |
9/30/2018 | N/A | -18 | -14 | -13 | N/A |
6/30/2018 | N/A | -11 | -11 | -11 | N/A |
3/31/2018 | N/A | -9 | -8 | -8 | N/A |
12/31/2017 | N/A | -8 | -6 | -6 | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: Insufficient data to determine if LOGC's forecast earnings growth is above the savings rate (2%).
Guadagni vs Mercato: Insufficient data to determine if LOGC's earnings are forecast to grow faster than the US market
Guadagni ad alta crescita: Insufficient data to determine if LOGC's earnings are expected to grow significantly over the next 3 years.
Ricavi vs Mercato: LOGC's revenue is expected to decline over the next 3 years (-132.5% per year).
Ricavi ad alta crescita: LOGC's revenue is forecast to decline over the next 3 years (-132.5% per year).
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: Insufficient data to determine if LOGC's Return on Equity is forecast to be high in 3 years time